Moderna announced mRNA-1345, an investigational RSV Vaccine, met primary efficacy endpoints in phase 3 trial
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
-
-
Three grizzly bears tested positive for highly pathogenic avian influenza in Montana
On Jan. 17, 2023, the Montana Fish and Wildlife Commission (FWP) reported that juvenile grizzly bears tested positive…
-
Roche announced EC approval of Xofluza for treatment and prevention of influenza in children aged one year and above
On Jan. 11, 2023, Roche announced treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. Post-exposure prophylaxis…
-
Paxlovid reduced serious risks from Omicron variants
On Jan. 10, 2023, the U.S. National Institutes of Health (NIH) reported that antiviral treatments can help reduce…
-
Spanish, Italian and French Health Authorities expanded recommendations for use of Novavax COVID-19 vaccine
On Jan. 5, 2023, Novavax announced that Spain’s Public Health Commission, Italy’s Ministry of Health, and France’s Haute…
-
Study reported major reservoir of resistance in wastewater of Southeast Asia, Western Pacific
On Jan. 1, 2023, a study published in the Lancet reported that concentrations of antibiotic residues found in…
-
Moderna finalized strategic partnership with UK government
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
-
Biotechnology | Diagnostics | Infectious Disease | Polio | Vaccine | WHO
Circulating vaccine-derived poliovirus type 2 (cVDPV2) reported in Indonesia
On Nov. 12, 2022, the World Health Organization (WHO) issued a Disease Outbreak News (DON) on the circulating…
-
EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
-
German Health Authority expanded recommendation for use of Novavax COVID-19 vaccine as a booster
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
-
Oxford Ebola vaccine manufactured and shipped in record time by Serum Institute of India
On Dec. 15, 2022, the University of Oxford’s Ebola vaccine candidate has been shipped to Uganda, just 80…
-
High path Avian influenza confirmed in Clackamas County backyard flock
On Dec. 12, 2022, the Oregon Department of Agriculture and the U.S. Department of Agriculture’s Animal Plant Health…
-
Texas Biomed added to national readiness and preparedness network
On Dec. 13, 2022, Texas Biomed announced that it had been designated as a prime contractor by the…
-
Swiss and French health authorities expanded recommendations for use of Nuvaxovid COVID-19 vaccine as booster
On Dec. 11, 2022, Novavax announced that the Switzerland’s Federal Office of Public Health and Francees Haute Autorite…
-
Ebola trial candidate vaccines arrived in Uganda in record 79 days after outbreak declared
On Dec. 9, 2022, the World Health Organization (WHO) announced that the first doses of one of the…
-
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | NIH | Non-Profit Research | Therapeutics | Vaccine
Hutchinson Cancer Center leads large-scale review of COVID-19 clinical trials that highlights multiple disparities
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
-
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
-
Highly pathogenic Avian influenza confirmed in Columbia County, Oregon
On Dec. 2, 2022, the Oregon Department of Agriculture (ODA) and the U.S. Department of Agriculture’s (USDA) Animal…
-
Novavax updated EUA listing for Novavax Nuvaxovid COVID-19 vaccine as pimary series in adolescents and as booster in adults
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
-
Wolves emboldened by parasite more likely to lead pack
On Nov. 27, 2022, it was reported a parasite that infects up to one-third of people around the…
-
Peru reported first severe bird-flu outbreak
On Nov. 18, 2022, the World Health Organisation for Animal Health (WHO) announced that Peru had reported its…
-
Novavax Nuvaxovid COVID-19 vaccine received expanded authorization in Canada as a booster in adults
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint
On Nov. 15, 2022, Moderna reported findings from a Phase II/III clinical trial where bivalent Omicron-targeting booster candidates,…
-
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Novavax phase 3 COVID-19 Omicron trial supported continued and future use of prototype vaccine as a booster
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
-
USDA confirmed highly pathogenic Avian influenza in commercial chickens in Mississippi
On Nov. 5, 2022, the U.S. Department of Agriculture’s (USDA) Animal Plant Health Inspection Service (APHIS) confirmed the…
-
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
-
Hologic announced contract with BARDA to support IVD approval of COVID assays
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
-
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
